Trailing Dividend / Share
$0.00
Barinthus Biotherapeutics plc (BRNS) Dividend History
Income profile from 2019 to 2025 with payout safety and yield-on-cost trend
Dividend Yield
N/A
Payout Ratio
N/A
Unknown
Dividend Streak
0 years
BRNS Dividend Income Check
Safety
Payout ratio data not available yet.
Consistency
0 straight years of dividend increases.
Income Trend
Yield on cost trend needs more history.
BRNS Dividend Scorecard
Yield & Income
Dividend YieldN/A
Trailing DPS$0.00
FrequencyN/A
Payments / 12M0
Payout Safety
Earnings PayoutN/A
Earnings SafetyUnknown
FCF PayoutN/A
FCF SafetyUnknown
Piotroski F-Score1/9
Growth
Growth Streak0 years
3Y CAGRN/A
5Y CAGRN/A
Yield on Cost (5Y)N/A
YOC Trendunknown
Total Returns
Buyback Yield0.0%
Total Shareholder Yield0.0%
1Y Total Return-32.3%
5Y Total Return-95.0%
Estimated $10K growth (return + dividends):
5Y ago$49510Y ago$47520Y ago$475
Uses precomputed total return metrics from screening data (not lot-by-lot dividend reinvestment transactions). BRNS's recent 5Y regime has been stronger than its full 10Y period, so 5Y can appear higher than 10Y.
BRNS Dividend History
No dividend payment history available
This company has not paid dividends during the available data period.
Dividend Analysis
Payout Safety
Barinthus Biotherapeutics plc has limited earnings payout data (Unknown).
Piotroski F-Score: 1/9 — weak financial health.
Growth Track Record
BRNS does not have a current streak of consecutive dividend increases.
Total Shareholder Returns
Beyond cash dividends, BRNS returns capital through share repurchases. The combined picture: 0.0% total shareholder yield.
Income Trend & Total Return
The 5-year total return is -95.0%.
DRIP Growth
A $10,000 investment made 10 years ago with dividends reinvested would have grown to approximately $475 today.
BRNS Annual Dividend History (2019–2025)
7 years of dividend data
GrowthDecline
| Year | DPS | YoY | Pmts | EPS | Payout | Coverage | YOC |
|---|---|---|---|---|---|---|---|
| 2025 | $0.00 | — | 0 | $-1.64 | — | — | — |
| 2024 | $0.00 | — | 0 | $-1.55 | — | — | — |
| 2023 | $0.00 | — | 0 | $-1.91 | — | — | — |
| 2022 | $0.00 | — | 0 | $0.14 | — | — | — |
| 2021 | $0.00 | — | 0 | $-1.37 | — | — | — |
| 2020 | $0.00 | — | 0 | $-2.24 | — | — | — |
| 2019 | $0.00 | — | 0 | $-436.87 | — | — | — |
See BRNS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BRNS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BRNS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBRNS — Frequently Asked Questions
Quick answers to the most common questions about buying BRNS stock.
How much dividend does BRNS pay per share?
Barinthus Biotherapeutics plc (BRNS) pays a trailing 12-month dividend of N/A per share, with a current dividend yield of N/A. Payments are made quarterly.
When is BRNS's next ex-dividend date?
BRNS's most recent ex-dividend date is N/A. You must own shares before the ex-dividend date to receive the next payment. BRNS typically pays dividends quarterly.
Is BRNS's dividend safe?
BRNS's dividend safety is rated "Unknown" based on an earnings payout ratio of N/A and FCF payout ratio of N/A. The dividend history does not yet show a prolonged growth streak.
How many years has BRNS increased its dividend?
BRNS has not maintained a consecutive growth streak recently. The 5-year dividend CAGR is N/A.
How often does BRNS pay dividends?
Barinthus Biotherapeutics plc pays dividends quarterly. The trailing 12-month total is N/A per share. Dividend data on this page covers 6+ years from 2019 to 2025.
How much would $10,000 invested in BRNS grow with dividend reinvestment?
With dividends reinvested (DRIP), $10,000 invested in BRNS five years ago would be worth approximately $495 today. This includes both price appreciation and compounded dividend reinvestment. Use the DRIP calculator above for other time periods.
What is BRNS's yield on cost for long-term holders?
BRNS's yield on cost — the current dividend divided by the original purchase price — is N/A for a 5-year holding period. This means long-term holders earn a higher effective yield than today's N/A market yield, thanks to the lower original cost basis.